The Experts below are selected from a list of 30 Experts worldwide ranked by ideXlab platform
Milap C. Nahata - One of the best experts on this subject based on the ideXlab platform.
-
Growth Hormone Use in Children with Idiopathic Short Stature
The Annals of pharmacotherapy, 2004Co-Authors: Karen L. Weise, Milap C. NahataAbstract:OBJECTIVE:To review the indication, pharmacology, pharmacokinetics, efficacy, and adverse effects of recombinant human growth hormone in children with idiopathic short stature (ISS).DATA SOURCES:A MEDLINE search (1966–December 2003) was performed using the key words human growth hormone, somatropin, Humatrope, normal children, Somatrem, and idiopathic short stature. Food and Drug Administration Advisory Committee Meeting minutes were also reviewed.STUDY SELECTION AND DATA EXTRACTION:The data presented in this review were obtained from published literature, abstracts presented at scientific meetings, and information on file with the manufacturer. Additional articles from these sources were also identified. Current issues of pediatric and endocrinology journals were reviewed for the most recent articles. Articles only addressing the use of growth hormone in normal, healthy children were used.DATA SYNTHESIS:Somatropin is indicated for use in children with ISS. Studies have shown modest benefit to final heigh...
Karen L. Weise - One of the best experts on this subject based on the ideXlab platform.
-
Growth Hormone Use in Children with Idiopathic Short Stature
The Annals of pharmacotherapy, 2004Co-Authors: Karen L. Weise, Milap C. NahataAbstract:OBJECTIVE:To review the indication, pharmacology, pharmacokinetics, efficacy, and adverse effects of recombinant human growth hormone in children with idiopathic short stature (ISS).DATA SOURCES:A MEDLINE search (1966–December 2003) was performed using the key words human growth hormone, somatropin, Humatrope, normal children, Somatrem, and idiopathic short stature. Food and Drug Administration Advisory Committee Meeting minutes were also reviewed.STUDY SELECTION AND DATA EXTRACTION:The data presented in this review were obtained from published literature, abstracts presented at scientific meetings, and information on file with the manufacturer. Additional articles from these sources were also identified. Current issues of pediatric and endocrinology journals were reviewed for the most recent articles. Articles only addressing the use of growth hormone in normal, healthy children were used.DATA SYNTHESIS:Somatropin is indicated for use in children with ISS. Studies have shown modest benefit to final heigh...
Ann Johanson - One of the best experts on this subject based on the ideXlab platform.
-
Factors predicting the response to growth hormone (GH) therapy in prepubertal children with GH deficiency.
The Journal of clinical endocrinology and metabolism, 1993Co-Authors: Sandra L. Blethen, R G Rosenfeld, Barbara M. Lippe, Peter Compton, Gilbert P. August, Ann JohansonAbstract:To identify factors influencing the response to GH therapy, we used a multiple regression model to analyze data from 632 naive prepubertal children with GH deficiency (GHD). There were 523 children with idiopathic and 109 children with organic GHD. They were treated with the same preparation of biosynthetic methionyl GH (Somatrem, Protropin) for at least 1 yr. In children with idiopathic GHD, six variables predicted 40% of the response to treatment. They were (listed in relative importance, all P < 0.0001): age, log maximum GH, weight adjusted for height, dosing schedule, dose, and midparental height. Three variables, pretreatment growth rate, log maximum GH, and age, predicted 20% of the GH response in children with organic GHD. When data for all children were analyzed using analysis of covariance, children with idiopathic GHD grew better than those with organic GHD (mean +/- SD, 9.2 +/- 2.4 vs. 8.8 +/- 2.6 cm/yr; P < 0.0001). The children (both organic and idiopathic GHD) who did not respond well to treatment were younger and thinner than those who did. Early diagnosis and initiation of therapy should be beneficial to ultimate height attainment. The best response to GH therapy should be in young children with severe idiopathic GHD who receive daily weight-adjusted doses. The use of GH daily in higher doses would be expected to be most beneficial in older children with acquired and/or less severe GHD or in children who are underweight for height.
Barbara M. Lippe - One of the best experts on this subject based on the ideXlab platform.
-
Treatment of Turner's Syndrome with Recombinant Human Growth Hormone (Somatrem)
Acta Paediatrica, 2008Co-Authors: Barbara M. Lippe, R G Rosenfeld, R L Hintz, A J Johanson, James W. Frane, B ShermanAbstract:This report extends to 3 years the prospective study of the effects of Somatrem alone or in combination with oxandrolone on growth in Turner's syndrome. Sixty-seven patients completed the 1-year study period during which all treatment groups had statistically increased height velocities as compared to the control group. Oral glucose tolerance and insulin responses remained unchanged after 1 year of Somatrem treatment. The group receiving oxandrolone experienced an increase in integrated glucose response and the group receiving combined therapy an increase in both integrated glucose and insulin responses. During the second and third years the Somatrem group remained on the same dose and treatment schedule and grew at mean velocities of 5.4 +/- 1.1 and 4.6 +/- 1.4 cm/year. The dose of oxandrolone was reduced by 50% during the second and third years for the combination group. The Somatrem dose remained unchanged. This group had height velocities of 7.4 +/- 1.4 cm and 6.1 +/- 1.5 cm/year. The control group and the group treated with oxandrolone alone were converted to combined therapy at the lowered oxandrolone dose. Their growth rates during the second year were 8.3 +/- 1.2 and 7.1 +/- 1.6 cm/year, respectively. Using bone age determinations and the methods of Bayley and Pinneau, all groups currently show predicted increases in final adult height.
-
Factors predicting the response to growth hormone (GH) therapy in prepubertal children with GH deficiency.
The Journal of clinical endocrinology and metabolism, 1993Co-Authors: Sandra L. Blethen, R G Rosenfeld, Barbara M. Lippe, Peter Compton, Gilbert P. August, Ann JohansonAbstract:To identify factors influencing the response to GH therapy, we used a multiple regression model to analyze data from 632 naive prepubertal children with GH deficiency (GHD). There were 523 children with idiopathic and 109 children with organic GHD. They were treated with the same preparation of biosynthetic methionyl GH (Somatrem, Protropin) for at least 1 yr. In children with idiopathic GHD, six variables predicted 40% of the response to treatment. They were (listed in relative importance, all P < 0.0001): age, log maximum GH, weight adjusted for height, dosing schedule, dose, and midparental height. Three variables, pretreatment growth rate, log maximum GH, and age, predicted 20% of the GH response in children with organic GHD. When data for all children were analyzed using analysis of covariance, children with idiopathic GHD grew better than those with organic GHD (mean +/- SD, 9.2 +/- 2.4 vs. 8.8 +/- 2.6 cm/yr; P < 0.0001). The children (both organic and idiopathic GHD) who did not respond well to treatment were younger and thinner than those who did. Early diagnosis and initiation of therapy should be beneficial to ultimate height attainment. The best response to GH therapy should be in young children with severe idiopathic GHD who receive daily weight-adjusted doses. The use of GH daily in higher doses would be expected to be most beneficial in older children with acquired and/or less severe GHD or in children who are underweight for height.
R G Rosenfeld - One of the best experts on this subject based on the ideXlab platform.
-
Treatment of Turner's Syndrome with Recombinant Human Growth Hormone (Somatrem)
Acta Paediatrica, 2008Co-Authors: Barbara M. Lippe, R G Rosenfeld, R L Hintz, A J Johanson, James W. Frane, B ShermanAbstract:This report extends to 3 years the prospective study of the effects of Somatrem alone or in combination with oxandrolone on growth in Turner's syndrome. Sixty-seven patients completed the 1-year study period during which all treatment groups had statistically increased height velocities as compared to the control group. Oral glucose tolerance and insulin responses remained unchanged after 1 year of Somatrem treatment. The group receiving oxandrolone experienced an increase in integrated glucose response and the group receiving combined therapy an increase in both integrated glucose and insulin responses. During the second and third years the Somatrem group remained on the same dose and treatment schedule and grew at mean velocities of 5.4 +/- 1.1 and 4.6 +/- 1.4 cm/year. The dose of oxandrolone was reduced by 50% during the second and third years for the combination group. The Somatrem dose remained unchanged. This group had height velocities of 7.4 +/- 1.4 cm and 6.1 +/- 1.5 cm/year. The control group and the group treated with oxandrolone alone were converted to combined therapy at the lowered oxandrolone dose. Their growth rates during the second year were 8.3 +/- 1.2 and 7.1 +/- 1.6 cm/year, respectively. Using bone age determinations and the methods of Bayley and Pinneau, all groups currently show predicted increases in final adult height.
-
Factors predicting the response to growth hormone (GH) therapy in prepubertal children with GH deficiency.
The Journal of clinical endocrinology and metabolism, 1993Co-Authors: Sandra L. Blethen, R G Rosenfeld, Barbara M. Lippe, Peter Compton, Gilbert P. August, Ann JohansonAbstract:To identify factors influencing the response to GH therapy, we used a multiple regression model to analyze data from 632 naive prepubertal children with GH deficiency (GHD). There were 523 children with idiopathic and 109 children with organic GHD. They were treated with the same preparation of biosynthetic methionyl GH (Somatrem, Protropin) for at least 1 yr. In children with idiopathic GHD, six variables predicted 40% of the response to treatment. They were (listed in relative importance, all P < 0.0001): age, log maximum GH, weight adjusted for height, dosing schedule, dose, and midparental height. Three variables, pretreatment growth rate, log maximum GH, and age, predicted 20% of the GH response in children with organic GHD. When data for all children were analyzed using analysis of covariance, children with idiopathic GHD grew better than those with organic GHD (mean +/- SD, 9.2 +/- 2.4 vs. 8.8 +/- 2.6 cm/yr; P < 0.0001). The children (both organic and idiopathic GHD) who did not respond well to treatment were younger and thinner than those who did. Early diagnosis and initiation of therapy should be beneficial to ultimate height attainment. The best response to GH therapy should be in young children with severe idiopathic GHD who receive daily weight-adjusted doses. The use of GH daily in higher doses would be expected to be most beneficial in older children with acquired and/or less severe GHD or in children who are underweight for height.